IINN vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IINN exhibits severe fundamental distress, characterized by a Piotroski F-Score of 4/9, which barely maintains a 'stable' rating despite catastrophic operational metrics. The company's operating margin of -4713.84% and a Price-to-Sales ratio of 64.07 indicate a massive disconnect between market valuation and actual revenue generation. With a 5-year price decline of 91% and a technical trend score of 0/100, the stock is in a persistent freefall. The absence of an Altman Z-Score and Graham Number further underscores the lack of positive earnings or stable equity to support a traditional valuation.
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
Compare Another Pair
Related Comparisons
IINN vs JNJ: Head-to-Head Comparison
This page compares Inspira Technologies Oxy B.H.N. Ltd. (IINN) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.